Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: The role of comparative studies and implications for future studies

Clinical Therapeutics

Volumn 29, Issue 6, 2007, Pages 1116-1127

  Cosman, Felicia ^a   Borges, Joao L C ^b   Curiel, Manuel Diaz ^c  

^a HELEN HAYES HOSPITAL   (United States)

^b Universidade Catolica de Brasilia   (United States)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

active comparator study; bisphosphonates; bridging study; monthly; study design; weekly

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; IBANDRONIC ACID; RISEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; HUMAN; MEDLINE; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS;

EID: 34547581275     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.06.009     Document Type: Note

References (62)

1. for the Fracture Intervention Trial Research Group. Black D., Cummings S., Karpf D., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
2. Brown J., Kendler D., McClung M., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71 (2002) 103-111
3. for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Chesnut III C., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
4. Cummings S., Black D., Thompson D., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
5. Delmas P., Recker R., Chesnut III C., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study. Osteoporos Int 15 (2004) 792-798
6. for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Harris S., Watts N., Genant H., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282 (1999) 1344-1352
7. for the Hip Intervention Program Study Group. McClung M., Geusens P., Miller P., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344 (2001) 333-340
8. Miller P., McClung M., Macovei L., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study. J Bone Miner Res 20 (2005) 1315-1322
9. for the Fosamax International Trial Study Group. Pols H., Felsenberg D., Hanley D., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Osteoporos Int 9 (1999) 461-468
10. for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Reginster J., Minne H., Sorensen O., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11 (2000) 83-91
11. for the Alendronate Once-Weekly Study Group. Schnitzer T., Bone H., Crepaldi G., et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12 (2000) 1-12
12. for the Alendronate Phase III Osteoporosis Treatment Study Group. Bone H., Hosking D., Devogelaer J., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
13. Sambrook P., Rodriguez J., Wasnich R., et al. Alendronate in the prevention of osteoporosis: 7-Year follow-up. Osteoporos Int 15 (2004) 483-488
14. Ste-Marie L., Sod E., Johnson T., and Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75 (2004) 469-476
15. Simon J., Lewiecki E., Smith M., et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study. Clin Ther 24 (2002) 1871-1886
16. Kendler D., Kung A., Fuleihan Gel H., et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48 (2004) 243-251
17. Simon J., Beusterien K., Hebborn A., et al. Bisphosphonate dosing preferences in women with postmenopausal osteoporosis: A study. Female Patient 30 (2005) 31-36
18. Emkey R., Koltun W., Beusterien K., et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21 (2005) 1895-1903
19. Cramer J., Amonkar M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21 (2005) 1453-1460
20. Recker R., Gallagher R., and MacCosbe P. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80 (2005) 856-861
21. Penning-van Beest F., Goettsch W., Erkens J., and Herings R. Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis. Clin Ther 28 (2006) 236-242
22. Abstract P-75. Siris E., Harris S., Silverman S., et al. Adherence to bisphosphonates (BPs) is associated with reduced fracture risk in women with postmenopausal osteoporosis (PMO). Menopause 12 (2005) 807
23. www.wma.net/e/policy/b3.htm
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for industry: E 10 Choice of control group and related issues in clinical trials. Available at. www.fda.gov/cber/gdlns/clincontr0501.pdf Accessed July 5, 2006.
25. Simon R. Are placebo-controlled clinical trials ethical or needed when alternative treatment exists [published correction appears in Ann Intern Med. 2000;133:754]. Ann Intern Med 133 (2000) 474-475
26. Temple R., and Ellenberg S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 133 (2000) 455-463
27. Ellenberg S., and Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Ann Intern Med 133 (2000) 464-470
28. for the Group for the Respect of Ethics and Excellence in Science (GREES). Delmas P., Calvo G., Boers M., et al. The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 13 (2002) 1-5
29. Brody B., Dickey N., Ellenberg S., et al. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis?. J Bone Miner Res 18 (2003) 1105-1109
30. Heaney R. Ethical issues in the design of osteoporosis clinical trials: The state of the question. J Bone Miner Res 18 (2003) 1117-1120
31. Ellenberg S. Scientific and ethical issues in the use of placebo and active controls in clinical trials. J Bone Miner Res 18 (2003) 1121-1124
32. Temple R. Study designs in osteoporosis. J Bone Miner Res 18 (2003) 1129-1132
33. Rosenblatt M. Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective. J Bone Miner Res 18 (2003) 1142-1145
34. Capron A., Donaldson S., Raisz L., and Swift S. Osteoporosis panel summary. J Bone Miner Res 18 (2003) 1160-1162
35. Reginster J., Abadie E., Delmas P., et al. Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int 17 (2006) 1-7
36. International Conference on Harmonisation E9 Expert Working Group. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Stat Med 18 (1999) 1905-1942
37. www.emea.eu.int/pdfs/human/ewp/055295.pdf
38. McAlister F., Laupacis A., Wells G., and Sackett D. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 282 (1999) 1371-1377
39. Jones B., Jarvis P., Lewis J., and Ebbutt A. Trials to assess equivalence: The importance of rigorous methods [published correction appears in BMJ. 1996;313:550]. BMJ 313 (1996) 36-39
40. www.emea.eu.int/pdfs/human/ewp/048299en.pdf
41. Kanis J., Alexandre J., Bone H., et al. Study design in osteoporosis: A European perspective. J Bone Miner Res 18 (2003) 1133-1138
42. Temple A., Benson G., Zinsenheim J., and Schweinle J. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther 28 (2006) 222-235
43. for the LIFE Study Group. Dahlof B., Devereux R., Kjeldsen S., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 (2002) 995-1003
44. Kanis J., Oden A., Johnell O., et al. Uncertain future of trials in osteoporosis. Osteoporos Int 13 (2002) 443-449
45. Fost N. Ethical issues in clinical research on fracture prevention in patients with osteoporosis. J Bone Miner Res 18 (2003) 1110-1115
46. for the Fracture Intervention Trial Research Group. Hochberg M., Ross P., Black D., et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42 (1999) 1246-1254
47. Sarkar S., Reginster J., Crans G., et al. Relationship between changes in biochemical markers of bone turn-over and BMD to predict vertebral fracture risk. J Bone Miner Res 19 (2004) 394-401
48. Eastell R., Barton I., Hannon R., et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 1051-1056
49. for the Fracture Intervention Trial Study Group. Bauer D., Black D., Garnero P., et al. Change in bone turn-over and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial. J Bone Miner Res 19 (2004) 1250-1258
50. Hochberg M., Greenspan S., Wasnich R., et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87 (2002) 1586-1592
51. Wasnich R., and Miller P. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85 (2000) 231-236
52. Miller P., Hochberg M., Wehren L., et al. How useful are measures of BMD and bone turnover?. Curr Med Res Opin 21 (2005) 545-554
53. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 80 (2005) 379-388
54. for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Ettinger B., Black D., Mitlak B., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial [published correction appears in JAMA. 1999;282:2124]. JAMA 282 (1999) 637-645
55. for the Alendronate Phase III Osteoporosis Treatment Study Group. Liberman U., Weiss S., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333 (1995) 1437-1443
56. October 14. US Dept of Health and Human Services. Office of the Surgeon General. Bone health and osteoporosis: A report of the Surgeon General. Available at: http://www.surgeongeneral.gov/library/bonehealth. Accessed June 4, 2007. (2004)
57. Delmas P., Adami S., Strugala C., et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis Rheum 54 (2006) 1838-1846
58. Cosman F., McClung M., Rosen C., et al. Rationale and design of the MOTION study (Monthly Oral Therapy with lbandronate for Osteoporosis iNtervention). J Bone Miner Res 20 Suppl 1 (2005) S398
59. Hosking D., Adami S., Felsenberg D., et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study. Curr Med Res Opin 19 (2003) 383-394
60. for the Fosamax Actonel Comparison Trial Investigators. Rosen C., Hochberg M., Bonnick S., et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20 (2005) 141-151
61. www.clinicaltrials.gov/ct/show/nct00247273?order=1
62. Bonnick S., Saag K., Kiel D., et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 91 (2006) 2631-2637